To determine the maximum-tolerated dose (MTD) of doxorubicin when given in combination with cisplatin and the multidrug-resistance (MDR) modulator valspodar and the remission rate induced by this combination in patients with platinum- and anthracycline-resistant ovarian cancer.
Department of Gynecologic Oncology, Norwegian Radium Hospital, and Department of Clinical Pharmacology, National Hospital, Oslo, Norway. mark.baekelandt@klinmed.uio.no
